VRTX vs REGN
VRTX and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $130.42B | — |
| P/E (TTM) | 30.0 | 19.1 |
| P/B | 6.44 | — |
| P/S | 10.9x | — |
| Revenue | $12.59B(TTM) | $15.53B(TTM) |
| Revenue growth (YoY) | 8.9% | 1.0% |
| Net income | $4.41B(TTM) | $4.33B(TTM) |
| Earnings growth (YoY) | 838.1% | 2.1% |
| EPS, diluted | $17.17(TTM) | $40.41(TTM) |
| EBIT margin | 34.8% | 24.9% |
| ROE | 19.5% | 14.2% |
| ROIC | 25.0% | 9.4% |
| 1y total return | +31.0% | +35.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: VRTX frente a REGN
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)